Editas Medicine Inc

NASDAQ:EDIT  
63.23
+2.23 (+3.66%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.47B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.1 Million
Adjusted EPS-$0.81
See more estimates
10-Day MA$63.12
50-Day MA$55.29
200-Day MA$50.66
See more pivots

Editas Medicine Inc Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.401.9000
Number of Employees: 235

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.